Published in Postgrad Med J on February 01, 1985
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med (1977) 1.93
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
The radical radiotherapy of regionally localized Hodgkin's disease. Radiology (1962) 1.58
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol (1984) 1.55
Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med (1981) 1.49
Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA (1981) 1.21
Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med (1982) 1.12
Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol (1984) 1.09
The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood (1982) 1.06
The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer (1978) 1.05
Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep (1982) 1.05
Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer (1980) 1.04
Intensive investigation in management of Hodgkin's disease. Br Med J (1976) 1.04
Radiotherapy in the treatment of Hodgkin's disease. Br Med J (1978) 1.01
The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer (1983) 1.00
Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) (1982) 0.99
Cytotoxic-induced ovarian failure in Hodgkin's disease. II. Effects on sexual function. JAMA (1979) 0.96
Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP). Cancer Chemother Pharmacol (1979) 0.95
Role of laparotomy and splenectomy in the management of Hodgkin's disease. Cancer (1972) 0.90
Staging laparotomy in Hodgkin's disease. Ann Surg (1978) 0.89
Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease. J Natl Cancer Inst (1981) 0.88
Second malignant neoplasms in patients treated for Hodgkin's disease with radiotherapy or radiotherapy and chemotherapy. Cancer (1981) 0.87
Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol (1979) 0.85
Posttreatment laparotomy as a guide to management in patients with Hodgkin's disease. Cancer Treat Rep (1982) 0.83
Chemotherapy in the treatment of Hodgkin's disease. Semin Hematol (1983) 0.80
Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys (1980) 0.78
Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharmacol Ther (1972) 0.77
Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer (1978) 0.77
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol (1975) 3.12
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Expression of human T and B lymphocyte cell-surface markers on leukaemic cells. Lancet (1974) 2.15
The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol (1988) 2.05
An orbital period of 0.94 days for the hot-Jupiter planet WASP-18b. Nature (2009) 1.79
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol (2001) 1.79
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
Emotional support for cancer patients: what do patients really want? Br J Cancer (1996) 1.72
The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol (2000) 1.68
Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet (1983) 1.66
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol (2003) 1.59
Central nervous system toxicity of interferon. Br J Cancer (1983) 1.58
The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol (1991) 1.55
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia (2005) 1.50
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol (1995) 1.48
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol (1998) 1.48
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood (1994) 1.44
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol (2000) 1.43
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature. Q J Med (1979) 1.42
HLA-DP based resistance to Hodgkin's disease. Lancet (1989) 1.42
Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol (1994) 1.41
Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol (1983) 1.40
Apparent removal of graft-versus-leukaemia effect by the use of leucocyte-poor blood components in patients with acute myeloblastic leukaemia. Br J Haematol (1989) 1.40
Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol (1986) 1.34
Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol (2001) 1.28
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol (1982) 1.26
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J (1978) 1.25
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia (2007) 1.22
Blast crisis of chronic myeloid leukaemia (CML). II. Cell surface marker analysis of "lymphoid" and myeloid cases. Br J Haematol (1976) 1.22
Renal involvement in patients with non-Hodgkin's lymphoma: clinical and pathological features in 23 cases. Hematol Oncol (1990) 1.21
Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer (1979) 1.18
Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia (2007) 1.17
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature (1987) 1.16
Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy. Br Med J (1974) 1.15
Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia (2007) 1.14
Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy. Br Med J (Clin Res Ed) (1988) 1.14
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol (2001) 1.12
Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol (1995) 1.12
A new member of the proprotein convertase gene family (LPC) is located at a chromosome translocation breakpoint in lymphomas. Cancer Res (1996) 1.10
Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J (1978) 1.06
Early central nervous system involvement in adults with acute non-myelogenous leukaemia. Br J Cancer (1977) 1.05
The treatment of acute myelogenous leukemia in adults. Semin Hematol (1982) 1.03
Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer (1988) 1.02
Distribution of T-lymphocyte subsets in Hodgkin's disease characterized by monoclonal antibodies. Br J Cancer (1982) 1.02
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia (2005) 1.02
Terminal transferase enzyme assay and immunological membrane markers in the diagnosis of leukaemia: a multiparameter analysis of 300 cases. Br J Haematol (1980) 1.01
Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang (1994) 1.01
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 1.00
Immunocytochemical demonstration of PTHrP protein in neoplastic tissue of HTLV-1 positive human adult T cell leukaemia/lymphoma: implications for the mechanism of hypercalcaemia. Br J Cancer (1991) 1.00
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol (1983) 0.99
Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) (1982) 0.99
Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol (1996) 0.99
Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol (2001) 0.98
Characteristics of Sternberg-Reed, and related cells in Hodgkin's disease: an immunohistological study. Br J Cancer (1984) 0.98
Lymphoma classification--the gap between biology and clinical management is closing. Blood (1996) 0.98
The Cotswolds report on the investigation and staging of Hodgkin's disease. Br J Cancer (1990) 0.97
Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood (1993) 0.96
Relation of "lymphoid" phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia. Cancer (1979) 0.95
Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia (2011) 0.94
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol (2001) 0.94
Localisation of a novel region of recurrent amplification in follicular lymphoma to an approximately 6.8 Mb region of 13q32-33. Genes Chromosomes Cancer (2001) 0.94
Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol (1986) 0.93
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol (1999) 0.93
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol (2000) 0.92
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J (2000) 0.92
Human T-cell leukemia virus (HTLV) in the United Kingdom. Int J Cancer (1984) 0.92
The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol (2000) 0.92
Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med (1986) 0.92
Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature. Leukemia (1992) 0.92
Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML). Cancer Chemother Pharmacol (1983) 0.92
The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol (1985) 0.92
High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol (2000) 0.91
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol (2000) 0.91
Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol (1999) 0.91
Asymptomatic carotid arterial disease in young patients following neck radiation therapy for Hodgkin lymphoma. Radiology (1999) 0.91
Treatment of acute lymphoblastic leukaemia in adults. Br J Haematol (1986) 0.90
The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol (1982) 0.90
Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2004) 0.90
Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet (1976) 0.89
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer (2001) 0.89
Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer (1991) 0.89
Short-term treatment for acute myelogenous leukaemia. Br Med J (Clin Res Ed) (1982) 0.89
Caribbean T-cell lymphoma/leukemia. Cancer (1984) 0.88